|
Asthma treatment passes trial
Investor’s Business Daily Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi (NYSE:SNY) jointly announced positive results from a phase 2 study of dupilumab in patients with moderate to severe uncontrolled asthma, who often struggle with daily symptoms and recurring … |
View full post on asthma – Google News